XTX Topco Ltd Purchases Shares of 1,488 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• XTX Topco Ltd has purchased 1,488 shares of Alnylam Pharmaceuticals, amounting to approximately $402,000, marking a growing interest from institutional investors in the biopharmaceutical company.
• CEO Yvonne Greenstreet recently sold 31,640 shares at an average price of $304.39, reducing her stake by 39.26% and leaving her with shares valued at nearly $14.9 million.
• Analysts have been bullish about Alnylam Pharmaceuticals, with numerous upgrades raising target prices significantly, leading to a consensus rating of "Moderate Buy" and an average target price of $403.92.

XTX Topco Ltd bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,488 shares of the biopharmaceutical company's stock, valued at approximately $402,000.

Other institutional investors also recently bought and sold shares of the company. S&CO Inc. raised its stake in shares of Alnylam Pharmaceuticals by 74.8% in the 1st quarter. S&CO Inc. now owns 10,050 shares of the biopharmaceutical company's stock valued at $2,713,000 after acquiring an additional 4,300 shares during the period. Banque Cantonale Vaudoise acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $1,007,000. Federated Hermes Inc. raised its position in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Federated Hermes Inc. now owns 264,173 shares of the biopharmaceutical company's stock valued at $71,332,000 after purchasing an additional 14,582 shares during the last quarter. Meeder Advisory Services Inc. raised its position in Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Meeder Advisory Services Inc. now owns 978 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 72 shares during the last quarter. Finally, Fiera Capital Corp raised its position in Alnylam Pharmaceuticals by 7.8% in the 1st quarter. Fiera Capital Corp now owns 17,212 shares of the biopharmaceutical company's stock valued at $4,648,000 after purchasing an additional 1,242 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Finally, Chardan Capital raised their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Four equities research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $403.92.

Alnylam Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:ALNY traded up $6.01 during trading on Wednesday, reaching $435.94. 1,160,654 shares of the company were exchanged, compared to its average volume of 943,958. The firm has a market capitalization of $57.14 billion, a PE ratio of -177.21 and a beta of 0.25. The business's fifty day simple moving average is $336.89 and its 200-day simple moving average is $286.99. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $445.20. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion for the quarter, compared to analyst estimates of $633.54 million. During the same period in the previous year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.